Centene / Ambetter denied your IVIG and immunoglobulin? Here is what to do next

Why Centene / Ambetter denies IVIG and immunoglobulin

Centene operates one of the largest Medicaid footprints in the U.S. and sells ACA marketplace coverage under the Ambetter brand. Marketplace plans drew elevated regulator and journalist scrutiny in 2024 for higher-than-average denial rates on in-network claims, and Centene-managed Medicaid lines vary plan-by-plan by state.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

What Centene / Ambetter denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

• IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
• Continuation after the initial authorization period when response is not documented
• Dose or frequency above the policy's stated range
• Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
• Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical Centene / Ambetter IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Diagnosis not on the plan's list of covered indications
• Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
• No documented failure of first-line therapy where the policy requires it
• Response to prior IVIG cycles not documented in measurable terms
• Plan classifies the use as experimental or investigational

The Centene / Ambetter appeal process

Appeal levels: Marketplace: internal appeal then federal external review (IRO). Medicaid: plan appeal then state fair hearing. Medicare Advantage: federal 5-level ladder.

Carrier timing: 180 days from denial for marketplace internal appeals; 4 months / 120 days for federal external review. Medicaid fair-hearing deadlines vary by state, often as short as 90-120 days.

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about Centene / Ambetter: We confirm the specific Centene subsidiary (Ambetter, Sunshine Health, Wellcare, etc.) before filing, because procedural rules and the supervising regulator change with the line of business.

Common Centene / Ambetter denial patterns for IVIG and immunoglobulin

• ACA marketplace in-network denials. Ambetter marketplace plans have been documented denying in-network medical claims at rates above the marketplace average. Federal ACA rules guarantee internal appeal plus external review via an Independent Review Organization (IRO), both are no-cost to the member.
• Narrow networks driving care-access denials. Ambetter HMO products often run narrower networks than the local competition. Network-adequacy challenges (state DOI complaints citing inadequate specialist access) can convert an out-of-network denial into in-network coverage.
• Medicaid managed care fair hearings. Centene-managed Medicaid plans (Sunshine Health, Buckeye, Peach State, etc.) operate under each state's Medicaid rules. After plan-level appeal, members have the right to a state fair hearing, a binding administrative process with strong reversal history.

How to win your Centene / Ambetter IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against Centene / Ambetter, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every Centene / Ambetter denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. Centene / Ambetter frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in Centene / Ambetter's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your Centene / Ambetter IVIG and immunoglobulin appeal

• The denial letter naming the criterion or policy applied
• Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
• Record of prior therapies and outcomes
• Infusion records showing dose, frequency, and documented response
• The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Centene / Ambetter IVIG and immunoglobulin appeals: frequently asked questions

What Apellica does for Centene / Ambetter IVIG and immunoglobulin appeals

We file appeals against Centene / Ambetter specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Centene / Ambetter appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related Centene / Ambetter guides

• Centene / Ambetter surgery denials appeal guide
• Centene / Ambetter mri and imaging denials appeal guide
• Centene / Ambetter medication and prescription denials appeal guide
• Centene / Ambetter medicare denials appeal guide

IVIG and immunoglobulin guides for other carriers

• UnitedHealthcare IVIG and immunoglobulin appeal guide
• Aetna (CVS Health) IVIG and immunoglobulin appeal guide
• Cigna (Evernorth) IVIG and immunoglobulin appeal guide
• Anthem / BlueCross BlueShield IVIG and immunoglobulin appeal guide